Journal Article

Visual and whole-body quantitative analyses of 68  Ga-DOTATATE PET/CT for prognosis of outcome after PRRT with 177 Lu-DOTATATE

Gardner, Linda, Sonni, Ida, Ciuca, Liliana, Nguyen, Kathleen, Lewis, Meredith, Hotta, Masatoshi, Thin, Pan, Hayrapetian, Artineh, Allen-Auerbach, Martin, Lubin, David

2024

Overview

Somatostatin receptors (SSTR) represent an ideal target for nuclear theranostics applications in neuroendocrine tumors (NET). Studies suggest that high uptake on SSTR-PET is associated with response to SSTR peptide receptor radionuclide therapy (PRRT). The purpose of this study was to evaluate the role of baseline whole-body (WB)  Ga-DOTATATE PET/CT (SSTR-PET) quantitative parameters, and the presence of NET lesions without uptake on SSTR-PET, as outcome prognosticator in patients with NET treated with PRRT. Patients with NET who underwent at least 4 Lu-DOTATATE PRRT cycles between 07/2016 and 03/2021 were included in this retrospective analysis if they fulfilled the following inclusion criteria: SSTR-PET within 6 months of 1st PRRT cycle, follow-up CT and/or MRI performed > 6 months after the 4th cycle of PRRT. The SSTR-PET analysis consisted of a visual and a quantitative analysis done independently by two board-certified physicians. The visual analysis assessed the presence of NET lesions visible on the SSTR-PET co-registered CT. The quantitative analysis consisted in contouring all SSTR-avid lesions on SSTR-PET and extracting WB quantitative parameters: SUVmean (WB-SUVmean), SUVmax of the lesion with highest uptake (H-SUVmax), and tumor volume (WB-TV). WB-SSTR-PET parameters and the presence of SSTR-PET-negative lesions were correlated to radiologic response (assessed by RECIST 1.1 criteria) and progression-free survival (PFS). Fisher's exact test, Mann-Whitney's U test and Kaplan-Meier curves with Cox-regression analysis were used for the statistical analysis. Forty patients (F/M: 21/19; 34/40 with gastro-entero-pancreatic (GEP) NET, 6/40 with non-GEP NET) were included in the analysis. The median follow-up period after the 4th PRRT cycle was 25.7 months (range 15.2-59.1). Fourteen/40 (35%) patients showed radiologic response (RECIST PR). PFS event was observed in 17/40 (42.5%) patients. Thirteen/40 (32.5%) patients had SSTR-PET-negative lesions at baseline. Higher WB-SUVmean and H-SUVmax were associated with better response (p = 0.015 and 0.005, respectively). The presence of SSTR-PET-negative lesions and lower WB-SUVmean were associated with shorter PFS (p = 0.026 and 0.008, respectively). Visual and quantitative analyses of baseline SSTR-PET can yield valuable information to prognosticate outcomes after Lu-DOTATATE PRRT.

• Subject: Humans / Neuroendocrine Tumors - diagnostic imaging / Neuroendocrine Tumors - pathology / Neuroendocrine Tumors - radiotherapy / Octreotide - therapeutic use / Organometallic Compounds - therapeutic use / Positron Emission Tomography Computed Tomography / Positron-Emission Tomography / Prognosis / Radionuclide Imaging / Receptors, Somatostatin / Retrospective Studies